By: Todd Neale, MedPage Today
I recently got back from the annual meeting of the American Society of Hypertension, where I witnessed a prime example of "getting ahead of yourself."
In a press conference Monday discussing the next morning's late-breaking clinical trials session to close out the meeting, we heard preliminary results from a pivotal trial of the Rheos Baroreflex Activation Therapy system, which is being developed by CVRx for treating resistant hypertension.
You can find a more complete description of the system on the company's website, but basically the device works by stimulating the baroreceptors at the bifurcation of the carotid arteries with an electrical current from a battery pack implanted in the chest. The stimulation causes the blood pressure to drop.
Click here to continue reading this post